Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 442-080-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 12.5 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- other: NAEC
- Value:
- 625 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Inhalation should not be a preferred route for absorption. Original value is NOAEL 125 mg/Kg, subchronic study in dog by oral administration of piperazine. Allometric scaling from dog to human is 1.4. The result is multiplied by 70Kg considered as the average weight of a human being (bw) and divided by 10m3/person considered as the average volume that is breathed in 8h exposure. Conclusion [(125 mg/Kg bw /1.4)*70Kg bw]/10 m3 = 625 mg/m3 bw (NAEC)
- AF for dose response relationship:
- 1
- Justification:
- not necessary
- AF for differences in duration of exposure:
- 2
- Justification:
- from subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Already considered (1.4)
- AF for other interspecies differences:
- 2.5
- Justification:
- Correction for possible differences in the ADME
- AF for intraspecies differences:
- 1
- Justification:
- Already considered (10)
- AF for the quality of the whole database:
- 2
- Justification:
- The data is extrapolated from the most concerning constituent, and not calculated on the substance itself
- AF for remaining uncertainties:
- 5
- Justification:
- precautionary AF to include possible contribution from other constituent
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.57 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 350
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 250 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- As reported in ECHA guideline, dermal absorption should not be higher than oral absorption
- AF for dose response relationship:
- 1
- Justification:
- not necessary
- AF for differences in duration of exposure:
- 2
- Justification:
- from subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1.4
- Justification:
- from dog
- AF for other interspecies differences:
- 2.5
- Justification:
- Correction for possible differences in the ADME
- AF for intraspecies differences:
- 5
- Justification:
- workers
- AF for the quality of the whole database:
- 2
- Justification:
- The data is extrapolated from the most concerning constituent, and not calculated on the substance itself
- AF for remaining uncertainties:
- 5
- Justification:
- precautionary AF to include possible contribution from other constituent
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - workers
This substance is a complex UVCB which is only partially bioavailable. DNEL for DG HF 2000 is derived from the most concerning constituent of th e soluble fraction, i.e. piperazine. This approach is derived from the NOAEL that was accepted by EMA for the use of piperazine as antihelminthic.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 6.25 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- other: NAEC
- Value:
- 312.5 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Inhalation should not be a preferred route for absorption. This substance is for industrial use only and handles only in controlled system. Exposure to general population has low probabilty. Original value is NOAEL 125 mg/Kg, subchronic study in dog by oral administration. Allometric scaling from dog to human is 1.4. The result is multiplied by 70Kg considered as the average weight of a human being (bw) and divided by 20m3/person considered as the average volume that is breathed for General Population. Conclusion [(125 mg/Kg bw /1.4)*70Kg bw]/0 m3 = 312.5 mg/m3 bw (NAEC)
- AF for dose response relationship:
- 1
- Justification:
- Not necessary
- AF for differences in duration of exposure:
- 2
- Justification:
- From subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Already considered (1.4)
- AF for other interspecies differences:
- 2.5
- Justification:
- Correction for possible differences in the ADME
- AF for intraspecies differences:
- 1
- Justification:
- Already considered (20)
- AF for the quality of the whole database:
- 2
- Justification:
- The data is extrapolated from th emost concerning constituent and not calculated on the substance itself
- AF for remaining uncertainties:
- 5
- Justification:
- Precautionary AF to include possible contribution from other constituents
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.79 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 700
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 250 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- as reported in ECHA guideline, dermal absorption should not be higher than oral absorption
- AF for dose response relationship:
- 1
- AF for differences in duration of exposure:
- 2
- Justification:
- from subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1.4
- Justification:
- from dog
- AF for other interspecies differences:
- 2.5
- Justification:
- Correction for possible differences in the ADME
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 2
- Justification:
- The data is extrapolated from the most concerning constituent and not calculated on the substance itself
- AF for remaining uncertainties:
- 5
- Justification:
- Precautionary AF to include possible contribution from other constituents
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
- Route of original study:
- Dermal
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Most sensitive endpoint:
- skin irritation/corrosion
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.179 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 700
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 125 mg/kg bw/day
- AF for dose response relationship:
- 1
- Justification:
- not necessary
- AF for differences in duration of exposure:
- 2
- Justification:
- From subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1.4
- Justification:
- from dog to human
- AF for other interspecies differences:
- 2.5
- Justification:
- Correction for possible differences in the ADME
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 2
- Justification:
- The data is extrapolated from the most concerning constituent and not measured on the substance itself
- AF for remaining uncertainties:
- 5
- Justification:
- Precautionary AD to include possible contribution from other constituent
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
- Value:
- 2 000 mg/kg bw/day
- Most sensitive endpoint:
- acute toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 40
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 50 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Not necessary
- AF for dose response relationship:
- 1
- Justification:
- not necessary
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- from rat
- AF for other interspecies differences:
- 1
- Justification:
- not necessary
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 1
- Justification:
- Test performed on the registered substance
- AF for remaining uncertainties:
- 1
- Justification:
- Test performed on the registered substance. No signd of toxicity
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- low hazard (no threshold derived)
Additional information - General Population
This substance is a complex UVCB which is only partially bioavailable. DNEL for DG HF 2000 is derived from the most concerning constituent of th e soluble fraction, i.e. piperazine. This approach is derived from the NOAEL that was accepted by EMA for the use of piperazine as antihelminthic. Moreover, this substance is for industrial use only and no exposure to general population is expected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.